Longitudinal changes in a blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in cirrhosis
Background and Aims: Hepatocellular carcinoma (HCC) risk in patients with cirrhosis can be predicted by cross-sectional assessment of biomarkers and/or clinical scores, including the Prognostic Liver Secretome signature (PLSec)-based PAaM score. However, HCC risk may change over time, potentially limiting the accuracy of cross-sectional risk prediction. We aimed to evaluate whether longitudinal changes in HCC risk biomarkers/scores improve upon one-time risk assessment. Approach and Results: In this nested case-control study within the multi-center prospective National Cancer Institute HCC Early Detection Strategy (HEDS) cohort of patients with cirrhosis, we evaluated longitudinal changes in PLSec over 1 or 2 years. Paired baseline and follow-up serum samples were available for 31 cases and 93 controls for 1-year changes, and for 25 cases and 75 controls for 2-year changes. Cross-sectional PLSec scores were higher in cases than in controls at baseline, Year 1, and Year 2 ( p <0.05). The 2-year change in PLSec score (delta-PLSec-Y2) was higher in cases than in controls ( p =0.026; AUROC, 0.65; adjusted odds ratio, 1.47 [95% CI, 1.04–2.15]). In multivariable logistic regression, delta-PLSec-Y2 remained significantly associated with HCC risk ( p =0.041) along with baseline PAaM. Conclusions: Longitudinal assessment of PLSec at a 2-year interval may provide additional information to refine cross-sectional HCC risk assessment, warranting further independent validation, evaluation of longer intervals, and exploration of optimal re-testing frequency.
Authors
- Stephanie Page-Lester
- Yujin Hoshida (ORCID: https://orcid.org/0000-0001-9430-1426)
- Jorge A. Marrero (ORCID: https://orcid.org/0000-0001-9604-5454)
- Amit G. Singal (ORCID: https://orcid.org/0000-0002-1172-3971)
- Hiroaki Kanzaki (ORCID: https://orcid.org/0000-0002-5039-9166)
- Naoto Fujiwara (ORCID: https://orcid.org/0000-0002-4109-3421)
- Indu Raman (ORCID: https://orcid.org/0000-0001-8469-3112)
- Courtney Katz (ORCID: https://orcid.org/0009-0007-9323-6766)
- Camden Lopez (ORCID: https://orcid.org/0000-0003-4516-8088)
- Lewis Rowland Roberts (ORCID: https://orcid.org/0000-0001-7885-8574)
- K. Rajender Reddy (ORCID: https://orcid.org/0000-0002-4898-7778)
- Neehar D. Parikh (ORCID: https://orcid.org/0000-0002-5874-9933)
- Ziding Feng (ORCID: https://orcid.org/0000-0003-3051-8882)
- Ece Janet Dinç (ORCID: https://orcid.org/0000-0003-1770-3178)
- Hiroyuki Suzuki (ORCID: https://orcid.org/0000-0003-2383-5038)
- Prithvi Raj (ORCID: https://orcid.org/0000-0003-4068-4358)
- Pratibha Selvakumar
Institutions
- Mayo Clinic (US)
- Mie University (JP)
- University of Michigan (US)
- Fred Hutch Cancer Center (US)
- Michigan Medicine (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/hc9.0000000000001081
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00